Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils.

Autor: Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Garasa S; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Ochoa MDC; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Olivera I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Glez-Vaz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Andueza MP; Departments of Oncology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain., Migueliz I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Alvarez M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Rodríguez-Ruiz ME; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Departments of Oncology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain., Rouzaut A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Sanmamed MF; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Departments of Oncology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain., Perez Gracia JL; Departments of Oncology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Departments of Oncology and Immunology, Clinica Universidad de Navarra, Pamplona, Spain.

Publikováno v: European journal of immunology [Eur J Immunol] 2021 Sep; Vol. 51 (9), pp. 2274-2280. Date of Electronic Publication: 2021 Jun 04.